Clinical Trial Update: Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial comparing a PARP inhibitor with Doxil in BRCA-positive advanced ovarian cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Doxil (liposomal doxorubicin)
• PARP inhibitor

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2016-06-03